newsfilter
← Latest News
Business Wire·

Personalis Announces Medicare Coverage for Ultrasensitive MRD Test in Breast Cancer

Personalis, Inc. (NASDAQ:PSNL), a leader in advanced genomics for precision oncology, today announced Medicare coverage of its ultrasensitive NeXT Personal® test for surveillance of cancer recurrence in breast